Detalhe da pesquisa
1.
Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa.
Br J Clin Pharmacol
; 90(5): 1247-1257, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38332460
2.
Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
Clin Infect Dis
; 76(8): 1492-1495, 2023 04 17.
Artigo
Inglês
| MEDLINE | ID: mdl-36519389
3.
Slow and Steady But Not Related to HIV Stigma: Physical Activity in South Africans Living with HIV and Chronic Pain.
AIDS Behav
; 27(6): 1950-1961, 2023 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-36436140
4.
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
N Engl J Med
; 381(9): 803-815, 2019 08 29.
Artigo
Inglês
| MEDLINE | ID: mdl-31339677
5.
Pharmacokinetic and pharmacogenetic associations with dolutegravir neuropsychiatric adverse events in an African population.
J Antimicrob Chemother
; 77(11): 3110-3117, 2022 10 28.
Artigo
Inglês
| MEDLINE | ID: mdl-36031789
6.
Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection.
J Antimicrob Chemother
; 77(10): 2706-2712, 2022 09 30.
Artigo
Inglês
| MEDLINE | ID: mdl-35953881
7.
Concentration-response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy.
Br J Clin Pharmacol
; 88(3): 883-893, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34954840
8.
Quality of life and associated factors among people receiving second-line anti-retroviral therapy in Johannesburg, South Africa.
BMC Infect Dis
; 22(1): 456, 2022 May 12.
Artigo
Inglês
| MEDLINE | ID: mdl-35550020
9.
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.
Clin Infect Dis
; 73(11): e3902-e3909, 2021 12 06.
Artigo
Inglês
| MEDLINE | ID: mdl-32960272
10.
Corrigendum to: CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.
Clin Infect Dis
; 74(4): 755, 2022 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35099526
11.
Is laboratory screening prior to antiretroviral treatment useful in Johannesburg, South Africa? Baseline findings of a clinical trial.
BMC Public Health
; 17(Suppl 3): 445, 2017 Jul 04.
Artigo
Inglês
| MEDLINE | ID: mdl-28832288
12.
Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens.
Open Forum Infect Dis
; 11(3): ofae007, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38529213
13.
Risks of metabolic syndrome in the ADVANCE and NAMSAL trials.
Front Reprod Health
; 5: 1133556, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37791109
14.
Clinical and virologic response to episodic acyclovir for genital ulcers among HIV-1 seronegative, herpes simplex virus type 2 seropositive African women: a randomized, placebo-controlled trial.
Sex Transm Dis
; 39(1): 21-4, 2012 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-22183840
15.
Comparing Prospective Incident Severe Acute Respiratory Syndrome Coronavirus 2 Infection Rates During Successive Waves of Delta and Omicron in Johannesburg, South Africa.
Open Forum Infect Dis
; 9(12): ofac587, 2022 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-36540387
16.
Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial.
AIDS
; 35(Suppl 2): S173-S182, 2021 12 15.
Artigo
Inglês
| MEDLINE | ID: mdl-34848584
17.
High individual pain variability in people living with HIV: A graphical analysis.
Eur J Pain
; 25(1): 160-170, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32939898
18.
Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa.
AIDS
; 35(2): 205-211, 2021 02 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33086234
19.
Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase.
Nat Commun
; 11(1): 5922, 2020 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33262331
20.
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Lancet HIV
; 7(10): e666-e676, 2020 10.
Artigo
Inglês
| MEDLINE | ID: mdl-33010240